PharmiWeb.com - Global Pharma News & Resources

General - Press Releases

Date Title Company
20-Oct-2025 PumasAI Named Best Clinical Pharmacology Tech Innovator 2025 by Global Health and Pharma for the Second Year in a Row PumasAI
20-Oct-2025 Applications of Nanoparticles in the Pharmaceutical and Biomedical Industries - 2 Day Online Training Course (Nov 12th - Nov 13th, 2025) - ResearchAndMarkets.com Businesswire
20-Oct-2025 Healthcare CMO Market Analysis Report 2025: Ongoing R&D Investments and Launch of Novel, Regulatory-Approved Contract Manufacturing Solutions - Forecast to 2029 - ResearchAndMarkets.com Businesswire
20-Oct-2025 Positive Safety and Efficacy of NI-1801 in Platinum Resistant Ovarian Cancer Patients Presented in Proffered Paper Oral Presentation at ESMO 2025 Businesswire
20-Oct-2025 Oscar Unveils New Choices and AI Tools Shaping the Future of Individual Healthcare for More Americans and Businesses Businesswire
20-Oct-2025 BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025 Businesswire
20-Oct-2025 SunRock Biopharma and Chime Biologics Announce Strategic Collaboration to Advance Development of Anti-CCR9 Antibody SRB5 Businesswire
20-Oct-2025 New Needle-Free Treatment Option for Life-Threatening Anaphylaxis, EURneffy®, Now Available in the UK Businesswire
20-Oct-2025 Iksuda Presents Encouraging IKS014 Phase 1 Data at ESMO Businesswire
20-Oct-2025 Genentech’s Tecentriq Showed Significant Overall and Disease-Free Survival Benefits in Bladder Cancer With ctDNA-Guided Treatment Businesswire
20-Oct-2025 FDA Approves Genentech’s Gazyva for the Treatment of Lupus Nephritis Businesswire
20-Oct-2025 Sustainability and innovation key themes across Lab Innovations’ speaker lineup Lab Innovations
20-Oct-2025 Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia Businesswire
19-Oct-2025 Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial Businesswire
19-Oct-2025 ESMO 2025: Faeth Therapeutics’ Phase 2 DICE Trial Shows 34% Reduction in Risk of Disease Progression with Oral Sapanisertib Plus Chemotherapy Businesswire
19-Oct-2025 XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer Businesswire
19-Oct-2025 Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer Businesswire
18-Oct-2025 KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery Businesswire
18-Oct-2025 Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025 Businesswire
18-Oct-2025 Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer Businesswire